Replies to post #65570 on Anavex Life Sciences Corp (AVXL)

[orveko_inc]

A2-73 has the potential to counter the side effects of donepezil. There are/were less that 5 patients (if I recall correctly) on A2-73 alone in the 2a trial, so any read on efficacy is inconclusive. Anavex reported what they had, but they need a larger sample size to make any real comparisons. A Notice of Allowance for one of the Plus applications would be enormous. A2-73 alone may only have a run time (in terms of exclusivity) of four years should it eventually receive FDA approval. A Plus patent would effectively triple or quadruple that.